Abstract
BackgroundThe new Long-acting injectable dual therapy (cabotegravir + rilpivirine) has been shown to improve quality of life and/or adherence in virologically controlled patients already undergoing antiretroviral therapy (ART). However, several...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
